As part of this arrangement, Recipharm will also acquire Alcon’s manufacturing facility located in Kaysersberg, France.
The 260 people currently employed at the Kaysersberg site would transfer and continue to be offered employment by Recipharm following the date of the sale.
Further details will be made available following the end of consultation with the Works Council of Alcon and finalisation of the negotiations.
Recipharm is a contract development and manufacturing organisation in the pharmaceutical industry employing some 2,200 employees.
Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies.